Relmapirazin

Small moleculeexperimentalImaging agent

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2013 (NCT02098174)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1nc(C(=O)N[C@H](CO)C(=O)O)c(N)nc1C(=O)N[C@H](CO)C(=O)O
Mol. weight
372.29 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • mp-3180

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07080008Phase 1Jan 31, 2026MediBeacon
NCT05943977Phase 3Mar 2, 2023Hangzhou Zhongmei, MediBeacon, Soochow University, Xuzhou Medical University
NCT02098187Phase 1Mar 1, 2014MediBeacon
NCT02098174Phase 1Nov 1, 2013MediBeacon, University of Maryland
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MediBeaconFor profit4322013
Hangzhou ZhongmeiFor profit1112023
Soochow UniversityAcademic/Hospital1012023
University of MarylandAcademic/Hospital1012013
Xuzhou Medical UniversityAcademic/Hospital1012023
5 organizations
Page 1 / 1